SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to its FDA-approved drug for a specific type of leukemia, though the drug carries warnings about potentially fatal side effects, leading to concerns about its safety profile.  Despite these concerns, some community members believe the drug's approval doubles its addressable market and view this as a long-term play, while others suggest a potential acquisition. Discussions also include potential market manipulation and the possibility of a short squeeze.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is experiencing volatility, with community members noting a lack of clear news catalysts for recent price swings. Despite broader market rallies, $TTD struggles to hold gains, leading to frustration among investors and speculation about market manipulation. Some investors point to a potential inverse head and shoulders pattern and analyst price target reiterations as positives, while others highlight the company's upcoming earnings release and potential benefits from shifts in the ad tech landscape.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to retail investors targeting a potential short squeeze, evidenced by high borrowing costs and significant social media discussion around depleting float. The community is actively discussing strategies to pressure short sellers, with some users calling for a coordinated effort to recall lent shares. Bullish sentiment seems tied to expectations around insiders increasing their positions.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc ($UUUU) is experiencing significant price volatility, driven by unusual options activity and discussions around its strategic positioning in the uranium and rare earth elements sectors. Community members are actively debating whether recent price movements are due to manipulation, insider trading, or broader market corrections, with some highlighting the company's potential to benefit from government contracts and the shift towards domestic resource independence. The stock's price action is also being influenced by news of a joint venture in Australia and increased investment in the company.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford's stock is trending downwards as a fire at a key aluminum supplier is expected to disrupt production, particularly for the profitable F-150 trucks. The community is debating whether this dip is an overreaction, a buying opportunity, or a sign of deeper issues with Ford's supply chain management and future guidance. Discussions also involve potential tariff relief and its impact on Ford's financials amid the aluminum shortage.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

DECK is trending as the stock experiences high volatility following earnings and revised guidance, sparking debate about its valuation and future growth prospects. Community discussion revolves around whether the dip presents a buying opportunity or if deeper issues with consumer demand and tariffs will continue to pressure the stock. Analysts are weighing in with mixed opinions, contributing to the uncertainty surrounding DECK.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is gaining attention due to recent news of insider buying and a milestone payment from Merck, sparking discussions about its low float and potential for a short squeeze. The community is actively analyzing the stock's setup, watching for a breakout, with some eyeing a potential run toward double digits. However, the possibility of a near term offering is also being discussed.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as analysts are raising price targets, citing increasing DRAM prices and AI demand, with UBS setting a target of $245 and Citi at $240. The community is closely watching for a breakout above $200 and speculating about potential partnerships, particularly with OpenAI, while also weighing its removal from the Chinese server market. Bullish sentiment revolves around Micron's undervalued status compared to its peers and the expectation of strong earnings reports driving further gains.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

PMI is trending as traders react to a recent price drop, with some citing a company statement addressing the decline and others pointing to a potential misunderstanding of a recent SEC filing regarding share dilution. The community is actively debating whether the stock represents a long-term value opportunity, while also questioning if the volatility is related to a pump-and-dump scheme. Some traders are reporting difficulty buying shares on certain platforms, further fueling speculation.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp is trending amid discussions of a potential Newmont takeover of Barrick's Nevada gold assets and Scotiabank upgrading its rating to Sector Outperform. Community members are also discussing the company's solid liquidity and potential merger opportunities. Some are also pointing out recent job cuts with others expecting gold to soar further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Paris, France-based Abivax SA (ABVX) spiked by over 400% in Wednesday's early premarket session following a positive late-stage readout from the clinical-stage biotech.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax stock</a> improved further into the ‘extremely bullish’ territory (98/100), with the message volume score spiking to a near-perfect “99,” suggesting ‘extremely high’ retail chatter.<figure class="image"><img style="aspect-ratio:626/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_4_32_00_AM_png_77d276515d.webp" alt="Screenshot 2025-07-23 at 4.32.00 AM.png" width="626" height="56"><figcaption>ABVX sentiment and message volume as of 4:30 a.m., July 23 | source: Stocktwits</figcaption></figure>The Abivax stock stream on the platform saw a nearly 260% increase in watcher count over the 24 hours leading up to late Tuesday. The 24-hour message volume change was 3,900%.The stock was among the top five trending tickers on Stocktwits early Wednesday.The frenzied retail activity followed the small-cap biotech's announcement of positive topline results from two Phase 3 studies evaluating its obefazimod in adult patients with moderately to severely active ulcerative colitis (UC).Abivax evaluated a 50 mg once-daily oral dose of obefazimod, its lead candidate, in studies dubbed ABTECT 1 and ABTECT 2. The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.It also met all key secondary endpoints, demonstrating “highly statistically significant and clinically meaningful benefits.”The company said an ABTECT Maintenance trial is ongoing, with topline results expected in the second quarter of 2026. It added that out of the 1,275 patients randomized in the induction trials, 678 achieved a clinical response and were enrolled in part 1 of the maintenance trial.Abivax CEO Marc de Garidel said, “The strength of these results reinforces our belief in obefazimod, our first-in-class miR-124 enhancer, and its potential to become a transformative new treatment modality for patients with UC.”Contingent upon the 44-week maintenance trial producing successful results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Abiva engages in the development of therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.A bullish Stocktwits watcher flagged a potential move toward the $60-$80 level on Wednesday.<stembedurl>https://stocktwits.com/europetradefuture/message/622045234</stembedurl>Another user, who identified themselves as a UC patient, said, “The addressable market is huge and physicians are always looking for another treatment option aside from TNFs, JAKs, interleukins, etc — some of the biggest blockbuster drugs currently treat UC/Crohns.”<stembedurl>https://stocktwits.com/Jblack500/message/622027325</stembedurl>Abivax stock is up over 36.5% for the year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/south-korean-feels-the-heat-after-japan-inks-trump-trade-deal-officials-in-dc/ch8wK2GR5M7">South Korea Feels The Heat After Japan Inks Trump Trade Deal — Officials In DC To Salvage Terms Before August Deadline</a>

Artwork based on an endoscopic image of the colon affected by ulcerative colitis (Photo Courtesy of Juan Gartner via Getty Images)

Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results  — Retail Buzz Builds Around Blockbuster Potential

The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.

Equity

US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug

Investing.com-- U.S.-listed shares of French biotech firm  Abivax SA  (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.

Kepler Capital  Reaffirms Their Buy Rating on Abivax SA (0RA9)

In a report released on July 16, Justine Telliez from Kepler Capital maintained a Buy rating on Abivax SA (0RA9 Research Report), with a price ta...

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the...

Abivax reports 2023 financial results and operational update

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR...

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics...

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris and Nasdaq: ABVX) ( Abivax or the Company ), a...

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December...

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024...

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ABVX News

ABVXAbivax - ADR